Chart Rhythms

Follow the rhythm behind every market move.

News Center

Source articles powering Chart Rhythms.

Browse cached source articles used by the rhythm engine. Filter by ticker, sentiment, or keyword, then open the stock rhythm page for deeper daily, swing, and long-term analysis.

Cached Articles

7496

Tickers With News

507

Showing Now

Top Ticker

TSLA

Active filters:

Ticker: ABBVClear filters

Featured Tickers

Quick rhythm news shortcuts.

Jump straight into the most important tickers for testing and market coverage.

Search all stocks

JPM MA VEEV FICO NVDA AAPL MSFT TSLA

Ticker Filters

Browse by cached coverage.

These are the tickers with the most cached source articles right now.

Search all stocks

All TSLA: 159 C: 153 NVDA: 148 AAPL: 139 F: 136 MSFT: 116 A: 98 JPM: 97 MA: 96 VEEV: 84

44 source articles found.

Open Markets

ABBVNeutralCNBC • 2026-06-04Cached source

Final Trades: Abbvie, Entegris, Oracle and Apple

The Investment Committee give you their top stocks to watch for the second half.

Open Source Open Stock Rhythm

ABBVNeutralYahoo • 2026-06-04Cached source

Does Decnupaz Approval Validate ABBV's ADC Strategy in Oncology?

AbbVie's FDA approval of Decnupaz for BPDCN marks its first blood cancer ADC and expands a strategy built on deals and internal development.

Open Source

Loading Chart Rhythms

Source articles powering Chart Rhythms.

Quick rhythm news shortcuts.

Browse by cached coverage.

44 source articles found.

Final Trades: Abbvie, Entegris, Oracle and Apple

Does Decnupaz Approval Validate ABBV's ADC Strategy in Oncology?

Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know

AbbVie Gets EU Nod for Aquipta as Acute Treatment for Migraine

Final Trades: AbbVie, Goldman Sachs, Old Dominion and the IYE

AbbVie Inc. (ABBV) Announces EC Authorization of Expanded Label for VENCLYXTO®

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Johnson & Johnson Hopes to Dethrone AbbVie's Biggest Growth Driver. Here's Why Investors Shouldn't Panic

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie Stock: Is ABBV Outperforming the Healthcare Sector?

AbbVie Says EC Authorizes Expanded Label For VENCLYXTO To Include Use In Combination With Acalabrutinib And Use In Combination With Ibrutinib For The Treatment Of Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia

AbbVie (ABBV) Up 3.5% Since Last Earnings Report: Can It Continue?

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

AbbVie Inc. (ABBV) Presents at EU Clinical Trial Regulation: Latest Developments and Upcoming Opportunities Transcript

AbbVie Wins FDA Nod for Decnupaz for Rare Blood Cancer Indication

ABBV Stock Gains On Winning FDA Approval For Rare Blood Cancer Drug

How Did AbbVie's Oncology Portfolio Perform in Q1 Despite Headwinds?

Piper Sandler Raises Price Target on AbbVie (ABBV) Amid Strong IBD Pipeline Progress

Final Trades: AbbVie, Deckers and Goldman Sachs

Two Paths to Growth: Johnson & Johnson vs AbbVie

What's the Better Dividend Stock Today: AbbVie or Pfizer?

AbbVie Expands European Reach As Investors Weigh Dividend Support

AbbVie (ABBV): 10 Best Low Risk Stocks to Buy in 2026

AbbVie Announces Positive CHMP Opinion for MAVIRET® for the Treatment of Acute Hepatitis C Infection

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

Final trades: AbbVie, Millrose Properties, Archer-Daniels-Midland, GE Vernova and Estee Lauder

AbbVie cancer trials show responses in lung, prostate and myeloma

AbbVie, Merck, Astra among winners of EU drug recommendations this week

AbbVie (ABBV) Receives Positive EMA Opinion for Maviret Approval

Opinion: AbbVie Is the Best Dividend King to Buy in an Increasingly Uncertain Market

AbbVie's MAVIRET Receives Medicinal Products For Human Use's Recommendation Approval To Treat Acute Hepatitis C Infection

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

Laryngeal Cancer Market Research Report 2026-2036, Competitive Analysis of Major Players - Merck & Co., Pfizer, Novartis, and AbbVie

AbbVie Inc. (ABBV) Positioned for Long-Term Gains with IBD Pipeline Strength

AbbVie's Allergan Aesthetics Receives European Medicines Agency's Committee For Medicinal Products For Human Use's Positive Opinion Recommending Boey For Temporary Improvement In Appearance Of Moderate To Severe Lines Between Eyebrows At Maximum Frown

Hepatic Impairment Market Analysis Report 2026-2036 Featuring AbbVie, Astellas Pharma, Gilead Sciences, F. Hoffmann La Roche, and Takeda Pharmaceuticals

High Yield Healthcare Stocks: Why Pfizer, AbbVie, and Medtronic Are Worth Watching in 2026

AbbVie (ABBV) Price Target Lowered to $235 at Evercore ISI

AbbVie Inc stock (US00287Y1091): new oncology data and pipeline updates keep focus on long-term grow

2 Reasons to Like ABBV and 1 to Stay Skeptical

Polymyositis Market Research Report 2026-2036: Competitive Landscape is Dominated by Major Players Such As Teva Pharmaceuticals, Gilead Sciences, Roche, AbbVie, and Pfizer

Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock

Kernicterus Market Research and Forecast Report 2026-2036 Featuring Pfizer, F.Hoffmann La Roche,. Merck, AbbVie, AsteraZeneca, Abbott Laboratories, Sanofi, GlaxoSmithKline, Grifols

Here's How Neuroscience Drugs Boost AbbVie's Q1 Sales Growth